Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

近日，生物技术公司Metsera（股票代码：MTSR）成功在美国纳斯达克上市，表现令人瞩目。公司发行价为每股18美元，首日开盘价即大幅上涨至25.5美元，收盘时更是达到了26.5美元，较发行价上涨了47%。此次上市让Metsera的市值轻松突破28亿美元，成为市场关注的焦点。

雷递网 雷建平 ...

Metsera开盘价为25.5美元，较发行价上涨41.7%；收盘价为26.5美元，较发行价上涨47%；以收盘价计算，公司市值为27.81亿美元。 近期，医疗保健及生物医药企业频频在美股上市，Ascentage ...

Recent health news covers significant events like Pfizer's diversity program settlement, AstraZeneca's halted UK investment, ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...